The Riverside Company Invests in Avance Clinical
November 9, 2021
The Riverside Company has invested in Avance Clinical, a leading Australian contract research organisation (CRO), to support the company's regional and international expansion. The investment will help Avance accelerate its clinical trials business — including vaccine and gene-technology studies — with a particular focus on growth in North America and Asia.
- Buyers
- The Riverside Company
- Targets
- Avance Clinical
- Industry
- Healthcare Services
- Location
- South Australia, Australia
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Decera Clinical (Riverside) Invests in Onviv, Strengthening Scientific Activation Capabilities
July 28, 2026
Healthcare Services
The Riverside Company’s Decera Clinical invested in Onviv, Inc. The combination is intended to expand Decera Clinical’s healthcare insights and scientific engagement/medical communications capabilities, including accelerating Onviv’s go-to-market with Decera Clinical’s AI platform, ActivationOS.
-
Avance Clinical Acquires U.S.-Based LumaBridge
January 7, 2026
Healthcare Services
Avance Clinical, an Australian full‑service CRO, has acquired LumaBridge, a U.S.-based oncology-focused clinical research organization. The deal expands Avance's U.S. footprint and establishes LumaBridge as the foundation of Avance's global Oncology Center of Excellence, strengthening oncology clinical trial capabilities from early‑phase through later‑phase programs.
-
The Riverside Company Invests in CRIO, Inc.
May 21, 2024
Cloud & SaaS
The Riverside Company, via its Riverside Micro-Cap Fund, has made a growth investment in CRIO, Inc., a Boston-based provider of cloud-based eSource, CTMS and regulatory-compliance software for clinical trial sites, CROs and pharmaceutical/biotech sponsors. Riverside’s capital will support accelerated product development, broader product offerings and potential strategic acquisitions as CRIO scales.
-
The Riverside Company / Clinical Education Alliance Acquires liV Inc.
July 5, 2023
Healthcare Services
The Riverside Company has invested in Montreal-based liV Inc. as an add-on to its portfolio company Clinical Education Alliance (CEA). liV, a provider of evidence-based medical education and medical communications for pharmaceutical medical affairs teams, will help CEA expand its medical communications capabilities and establish a foothold in the Canadian market.
-
Avance Clinical Acquires C3 Research Associates to Expand into North America
September 6, 2022
Healthcare Services
Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.
-
The Riverside Company Acquires Clinical Education Alliance from Renovus Capital Partners
December 10, 2020
Healthcare Services
The Riverside Company has signed a definitive agreement to acquire a majority stake in Clinical Education Alliance (CEA), a Virginia-based provider of live and web-based continuing medical education (CME). Renovus Capital Partners sold its majority stake but will remain a minority investor; Riverside plans to expand CEA’s therapeutic areas, end-user base and technology offering to accelerate growth.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.